Clinical trials · source year
25 selected, source-linked clinical trial records dated 2020. This is selective source coverage, not a complete timeline.
25 selected records.
13 connected profiles.
25 distinct public records.
Cited chronology
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT03842202 at 2026-07-30T20:18:37.981Z. Its registry update date was 2020-12-24, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Linaclotide
PeptideScanner retained ClinicalTrials.gov record NCT02220348 at 2026-07-30T20:18:37.979Z. Its registry update date was 2020-12-19, and PeptideScanner's reviewed identity mapping was linaclotide.
Source: ClinicalTrials.gov ↗
Afamelanotide
PeptideScanner retained ClinicalTrials.gov record NCT04578496 at 2026-07-30T20:20:00.372Z. Its registry update date was 2020-11-19, and PeptideScanner's reviewed identity mapping was afamelanotide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT02404376 at 2026-07-30T20:20:00.368Z. Its registry update date was 2020-11-03, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02064582 at 2026-07-30T20:21:17.072Z. Its registry update date was 2020-10-12, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT02916433 at 2026-07-30T20:21:17.072Z. Its registry update date was 2020-10-08, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT02563353 at 2026-07-30T20:22:36.942Z. Its registry update date was 2020-09-18, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02059213 at 2026-07-30T20:22:36.939Z. Its registry update date was 2020-09-16, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT04129255 at 2026-07-30T20:22:36.942Z. Its registry update date was 2020-09-10, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Plecanatide
PeptideScanner retained ClinicalTrials.gov record NCT02706483 at 2026-07-30T20:24:11.156Z. Its registry update date was 2020-08-18, and PeptideScanner's reviewed identity mapping was plecanatide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT00551343 at 2026-07-30T20:25:27.243Z. Its registry update date was 2020-07-07, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT04303819 at 2026-07-30T20:26:41.665Z. Its registry update date was 2020-06-11, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT02650206 at 2026-07-30T20:26:41.666Z. Its registry update date was 2020-06-09, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT03770637 at 2026-07-30T20:27:50.524Z. Its registry update date was 2020-05-21, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Elamipretide
PeptideScanner retained ClinicalTrials.gov record NCT02788747 at 2026-07-30T20:27:50.521Z. Its registry update date was 2020-05-14, and PeptideScanner's reviewed identity mapping was elamipretide.
Source: ClinicalTrials.gov ↗
Lixisenatide
PeptideScanner retained ClinicalTrials.gov record NCT02640118 at 2026-07-30T20:27:50.520Z. Its registry update date was 2020-05-07, and PeptideScanner's reviewed identity mapping was lixisenatide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT02918279 at 2026-07-30T20:29:13.572Z. Its registry update date was 2020-04-27, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Linaclotide
PeptideScanner retained ClinicalTrials.gov record NCT02559206 at 2026-07-30T20:29:13.579Z. Its registry update date was 2020-04-24, and PeptideScanner's reviewed identity mapping was linaclotide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00002633 at 2026-07-30T20:29:13.591Z. Its registry update date was 2020-04-03, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00002864 at 2026-07-30T20:29:13.581Z. Its registry update date was 2020-04-01, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT04281680 at 2026-07-30T20:32:04.760Z. Its registry update date was 2020-02-24, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT04175665 at 2026-07-30T20:32:04.760Z. Its registry update date was 2020-02-21, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT02351232 at 2026-07-30T20:32:04.755Z. Its registry update date was 2020-02-12, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00226967 at 2026-07-30T20:33:20.622Z. Its registry update date was 2020-01-27, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Tesamorelin
PeptideScanner retained ClinicalTrials.gov record NCT02196831 at 2026-07-30T20:33:20.623Z. Its registry update date was 2020-01-27, and PeptideScanner's reviewed identity mapping was tesamorelin.
Source: ClinicalTrials.gov ↗